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“Two Beasts” (2017) 
Artist: Ben Day Todd. Acrylic, gouache on canvas 
“Two Beasts” is an exploration of form and colour. By adding and subtracting paint, pushing and pulling colour, 
new information is found and previously unknown dialogues are recorded 
 
Abstract  
Whether the nom de guerre is Mathematical Oncology, Computational or Systems Biology, 
Theoretical Biology, Evolutionary Oncology, Bioinformatics, or simply Basic Science, there is 
no denying that mathematics continues to play an increasingly prominent role in cancer 
research. Mathematical Oncology—defined here simply as the use of mathematics in cancer 
research—complements and overlaps with a number of other fields that rely on mathematics 
as a core methodology. As a result, Mathematical Oncology has a broad scope, ranging 
from theoretical studies to clinical trials designed with mathematical models. This Roadmap 
differentiates Mathematical Oncology from related fields and demonstrates specific areas of 
focus within this unique field of research. The dominant theme of this Roadmap is the 
personalization of medicine through mathematics, modelling, and simulation. This is 
achieved through the use of patient-specific clinical data to: develop individualized screening 
strategies to detect cancer earlier; make predictions of response to therapy; design adaptive, 
patient-specific treatment plans to overcome therapy resistance; and establish domain-
specific standards to share model predictions and to make models and simulations 
reproducible. The cover art for this Roadmap was chosen as an apt metaphor for the 
beautiful, strange, and evolving relationship between mathematics and cancer. 
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Introduction to the 2019 
Mathematical Oncology Roadmap 
Russell C. Rockne1 
1 Department of Computational and 
Quantitative Medicine, Division of 
Mathematical Oncology, City of Hope National 
Medical Center, Duarte, CA 91010, USA 
 
Mathematical Oncology—defined 
here simply as the use of mathematics in 
cancer research—has gained momentum in 
recent years with the rapid accumulation of 
data and applications of mathematical 
methodologies. The purpose of this 2019 
Mathematical Oncology Roadmap is to 
provide a forward-looking view of the field 
and to demonstrate specific areas of focus 
within this unique field of research. The topics 
presented here are not intended to be 
exhaustive, but rather to feature emerging, 
high-impact areas that have the potential to 
shape the direction of Mathematical Oncology 
in the next 5–10 years. The selected topics 
cover both theoretical and practical issues. 
 The dominant theme of this Roadmap 
is the personalization of medicine through 
mathematics, modelling, and simulation. This 
is achieved primarily through the use of 
patient-specific clinical data. In this Roadmap, 
mathematical approaches are used to: make 
individualized predictions of response to 
therapy; present data and simulation 
standards with the goal of creating 
reproducible models; and improve cancer 
screening to detect cancer earlier. These 
approaches are also used to predict and steer 
cancer evolution to guide the design of 
adaptive, patient-specific treatment plans 
that overcome therapy resistance, with the 
goal of turning incurable cancers into chronic, 
manageable conditions rather than fatal 
diseases. Each contribution is summarized in 
the order it appears: 
 
Personalizing medicine by merging 
mechanistic and machine learning models 
The role of Mathematical Oncology in the 
future of precision or personalized medicine is 
demonstrated through patient-specific 
mathematical modelling, analysis of patient-
specific clinical data, and patient-specific 
adaptive therapies. Hawkins-Daarud and 
Swanson demonstrate these principles by 
looking towards a future merging of 
mathematical modelling and machine 
learning, in which knowledge-based 
mechanistic modelling is used to guide and 
inform machine learning when data is sparse. 
Hawkins-Daarud and Swanson highlight the 
potential and the challenges of merging these 
fields of mathematical modelling and machine 
learning, with an application to primary brain 
cancers and clinical imaging data such as MRI. 
 
Setting data and model standards 
However successful a modelling or simulation 
method may be, if it cannot be deployed or 
used by other groups, it is of limited value. For 
Mathematical Oncology to achieve its highest 
impact, Sluka et al. argue that standards are 
needed for both data and mathematical 
models, to ensure interoperability, to leverage 
and build upon prior work, and ultimately to 
develop useful tools that can be used to study 
and treat cancer. Of course the use of 
standards in science is not new; however, 
data and model standardization in this 
domain face unique challenges, particularly 
with respect to spatial models. Sluka et al. 
identify the central challenges and potential 
advances afforded by the establishment of 
“FAIR” (Findable, Accessible, Interpretable, 
and Reusable) models in Mathematical 
Oncology.  
 
Turning tumour forecasting into a rigorous 
predictive science 
In addition to the challenges of developing 
and standardizing mathematical models of 
cancer growth and response to therapy, lies 
the “grand challenge of Mathematical 
Oncology”: to faithfully reproduce—and 
predict—the spatiotemporal dynamics of 
tumour growth. Similar to weather models 
that predict the path of a hurricane, Hormuth 
et al. call for the use of families of models in 
which the optimal model (or models) is 
selected with Bayesian methodologies and 
used to update patient-specific predictions 
over time. The goal of this approach is to 
establish a foundation for tumour forecasting 
as a rigorous predictive science through 
careful model selection and validation. 
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Modelling cancer screening and early 
detection 
Benjamin Franklin famously stated that “An 
ounce of prevention is worth a pound of 
cure.” Nowhere could this be truer than in 
cancer; however, nowhere else could this 
sentiment be more challenging to implement. 
Many serious issues face the field of early 
detection of cancer, including the risk of false 
negatives, false positives, and the possibility 
of transient early-stage cancers that are 
successfully defeated by the body’s immune 
system. However, Curtius and Al Bakir 
propose that mathematical models of 
carcinogenesis can be used to evaluate and 
predict the efficacy of screening strategies 
using multiscale approaches, with the 
ultimate goal of producing clinically actionable 
personalized cancer screening 
recommendations.  
 
Analysing cancer dynamics and the evolution 
of resistance 
As cancer cells grow into a malignant lesion or 
tumour, the cells evolve and accumulate 
mutations in their DNA. The analysis of 
evolutionary dynamics using mathematical 
models is a rich field that has many 
applications to cancer. Wodarz et al. identify 
the spatial structure of the tumour cell 
population as a critical challenge in modelling 
tumour evolution. In particular, they suggest 
that novel computational methodologies are 
required to simulate and predict tumour 
evolution at realistically large population sizes 
with realistically small rates of mutation. 
Here, Wodarz et al. use mathematical 
modelling to predict the evolution of resistant 
cells within the evolving cancer as a whole. 
 
Applying a single-cell view to cancer 
heterogeneity and evolution 
In contrast to the view taken by Wodarz et al., 
Aparicio et al. consider tumour evolution at 
single-cell resolution. Using single-cell 
genome sequencing data, Aparicio et al. 
present mathematical and computational 
methods to analyse single-cell data from a 
topological perspective. Low-dimensional 
projections, or visualisations, that are used to 
study high-dimensional single-cell sequencing 
data may give a misleading representation of 
the relationships between individual cells. 
Aparicio et al. use machine learning and 
algebraic topology to construct simplified 
skeleton graphs as approximations for the 
geometry of high-dimensional data. These 
sophisticated methodologies enable the 
examination of the heterogeneity of individual 
cells in a continuum of states, from 
normal/healthy to cancerous. The 
mathematics of topological data analysis 
combined with single-cell sequencing 
technologies provide a powerful tool to study 
fundamental aspects of cancer biology at an 
unprecedented resolution. 
 
Accurately representing metabolism in 
cancer progression 
Altered metabolism and metabolic 
reprogramming are hallmarks of cancer and 
are associated with cancer progression and 
therapeutic resistance. Due to the many 
interconnected metabolites, enzymes, 
regulatory mechanisms, and pathways, 
systems biology approaches have been used 
to study cell metabolism. Often, mathematical 
representations of cell metabolism use a 
constraint-based formalism that does not 
explicitly account for spatial-temporal 
variations. Finley proposes a multiscale 
approach to modelling kinetics and time-
varying heterogeneities that may arise in 
aberrant cell metabolism in cancer due to 
environmental fluctuations. She also proposes 
the use of patient-specific data and open 
source computational platforms that support 
data and model standards, with the ultimate 
goal of using these models to generate novel 
drug combinations and treatment strategies. 
 
Modelling and predicting patient-specific 
responses to radiation therapy 
Long before the rise of immunotherapy, the 
three pillars of cancer treatment were 
surgery, chemotherapy, and radiation 
therapy. Radiation remains a definitive and 
curative treatment for many cancers and is 
highly personalized, with radiation fields and 
doses sculpted to an individual patient’s 
anatomy and cancer. However, Enderling et 
al. show that radiation therapy outcomes may 
be predicted and improved using simple 
mathematical models that account for the 
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growth rate of the cancer and introduce the 
“proliferation-saturation index (PSI)”. The 
authors discuss challenges for the clinical 
adoption of this mathematically-defined, 
patient-specific, predictive response index, 
and consider the road ahead, which includes 
prospective randomized clinical trials.  
 
Pioneering evolutionary therapy 
In contrast to the optimization of radiation 
therapy, Anderson and Gatenby propose an 
entirely new pillar of cancer treatment: 
evolutionary therapy. In this paradigm, 
treatment schedule and dose are 
mathematically designed to reduce the 
possibility of treatment resistance. Instead of 
using the maximum tolerated dose, 
evolutionary therapy aims to give the 
minimum effective dose through repeated 
treatment cycles to maintain tumour control 
over extended periods of time. Early results 
from an evolutionary therapy clinical trial in 
prostate cancer, designed by the authors to 
include in silico “phase i” trials, suggest that 
the length of treatment cycles is highly 
patient-specific and may be predicted with 
mathematical modelling.  
 
Exploring fitness landscapes and 
evolutionary game theory 
The principles of evolutionary therapy and 
therapeutic resistance can be modelled 
mathematically using evolutionary game 
theory (EGT), in which evolution is 
determined by a selection or optimisation of 
“fitness”. A fitness landscape is a conceptual 
and mathematical abstraction that enables 
predictions and interpretations of the 
temporal process of evolution. However, 
significant practical and theoretical challenges 
prevent the measurement or inference of the 
exact geometry of the fitness landscape. 
Kaznatcheev et al. propose that we reconsider 
the very concept of abstraction itself in order 
to better understand and use the EGT 
framework to guide evolutionary therapy, 
using algorithmic computer science as a 
practical example.  
 
In contrast, Krishnan et al. demonstrate a 
practical method to experimentally estimate 
the parameters of an EGT model, with the 
goal of designing combination therapies that 
not only avoid therapeutic resistance but are 
even able to steer cancer evolution on a 
patient-specific basis. The authors 
hypothesize—and demonstrate—how EGT-
driven therapies can be practically 
implemented in the clinic to overcome 
therapeutic resistance in cancer treatment.  
 
Summary 
In summary, this 2019 Mathematical 
Oncology Roadmap identifies three critical 
milestones along the path to mathematically 
designed cancer treatment: 1) obtaining 
accurate, rigorous, and reproducible 
predictions of the spatial-temporal 
progression of cancer; 2) avoiding and 
mitigating therapeutic resistance; and 3) 
merging mechanistic knowledge-based 
mathematical models with machine learning. 
Surprisingly, despite the advent of the era of 
“big data”, we are learning that we still lack 
the right kind of data. Big data in cancer is 
often taken from a single point in time and 
space, from only one biological scale, or 
without an appropriate micro-environmental 
context. The road ahead includes continued 
development of knowledge-based 
mathematical models and methods to bridge 
big data to the ideal of personalized, 
predictive, adaptive therapy. 
 
As we look towards the next 5–10 years in 
Mathematical Oncology, we note that 
government agencies such as the Federal 
Drug Administration (FDA) in the United 
States have begun to officially recognize 
modelling and simulation as forms of valid 
scientific evidence in the review and approval 
process. From our perspective, with the 
support and adoption of government 
regulatory agencies that recognize these 
methodologies, tumour forecasting, patient-
specific adaptive therapies with the use of in 
silico treatment scenarios, virtual clinical 
trials, and mathematical modelling and 
simulation have the potential to accelerate 
our scientific progress in cancer research, and 
also have the potential to transform the way 
we detect and treat cancer in the clinic. 
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The Future of Personalization in 
Mathematical Oncology: A 
Mathematical Merger of 
Mechanistic and Machine Learning 
Models 
Andrea Hawkins-Daarud1, Kristin R. 
Swanson1,2 
1 Mayo Clinic, Phoenix, Arizona 
2 Arizona State University, Tempe, Arizona 
Status 
Cancer patient care is intrinsically 
multidisciplinary. Tumor board is the clinical 
environment used to bring together those 
different disciplines to make treatment 
decisions, but, unfortunately, it is an agonizing 
environment of doubt – Is the tumor 
progressing? Is the optimal treatment A or B? 
All it takes is a brief experience in a tumor 
board to feel the injustice of a cancer 
diagnosis and the frustration of not knowing 
the truly optimal treatment. Every patient is 
unique and every patient will respond 
differently to the same treatment protocol. 
Thus, the central tumor board challenge is - 
how do we best integrate the unwieldy 
multitude of dispersed data (imaging, tissue, 
blood, molecular) to generate optimal clinical 
decisions for each patient? The current 
strategy for grappling with this complexity is 
to average over cohorts of seemingly similar 
patients with similar diagnoses to select an 
average treatment applied to an average 
patient with average outcomes. Yet, it is 
empirically evident that cancer is a complex 
evolving system that does follow some rules 
that are known and can be modeled and 
predicted mathematically in each patient. For 
instance, we know that cancer is a 
proliferative process that outcompetes the 
otherwise normal tissue to grow. Cancer cells 
have the ability to engage and co-opt their 
local environment to their benefit for growth 
and invasion. While these cancer cells hack 
normal rules of biology to their advantage, 
other known or identifiable biological and 
physical rules drive and/or constrain 
phenotypes. Based on these processes, the 
seemingly unwieldy cancer process can be 
formalized as mathematical equations which 
can be parametrized for each patient’s data 
(e.g. imaging, molecular, tissue). Every cancer 
patient deserves their own individualized 
equation (TEDx: http://bit.ly/1p1pl8A), a 
personalized parameterization of their disease 
evolution that can be exploited to guide and 
optimize his or her care. 
 
Current and Future Challenges 
The potential machine learning (ML) or 
artificial intelligence (AI) applications to 
healthcare have recently received particular 
notice in the media with IBM’s Watson, 
applications to radiology and diagnoses aided 
by wearable technology amongst many 
others. Each of these examples are exciting, 
but the full promise of personalized medicine 
remains unrealized. While the amount and 
types of clinical data being generated for each 
cancer patient is increasing dramatically, 
there are no holistic approaches or algorithms 
available that can incorporate all this data to 
identify the best treatment for each individual 
patient. There are, obviously, many reasons 
for this, but a critical challenge is that cancer 
is a spatially complex, adaptive process and 
the data being collected, while vast, is quite 
limited in that it is showing, at best, 
infrequent snapshots of extremely small 
regions of the tumor. Ultimately, this means 
AI and ML models will not be able to be 
trained on the right data to make reliable 
predictions.  
Mechanistic models can help. Cancer is 
fundamentally a physical process subject to 
the same predictable laws of nature studied in 
physics and chemistry. Of course, it is also a 
biological, multicellular evolving ecosystem 
with critical events happening on an 
enormous range of spatial and temporal 
scales from improper DNA methylation to the 
alteration of an organ’s function. These 
complex interacting components complicate 
the interpretation of data and experimental 
planning. While there are many fields of 
cancer research, mathematical oncology, a 
field dominated by mechanistic models, is 
arguably the best equipped to abstract 
overarching principles and develop a deeper 
understanding of how the mechanisms driving 
cancer can be exploited and shut down. To 
date, however, there are few models that 
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have bridged the scales necessary to fully 
utilize all the data generated. Thus, these 
models provide insight, but are not 
necessarily adapted to assimilate the breadth 
and depth of the data.  
Advances in Mathematics, Technology, or 
Data to Meet Challenges 
These two approaches, insightful mechanistic 
models and the powerful black box of 
machine learning, are highly complementary. 
A grand challenge of our day is to develop 
methods leveraging both their strengths to 
create a symbiotic modeling paradigm such 
that its whole is greater than the sum of its 
parts - one that can both leverage the vast 
data at our fingertips (machine learning) but 
also the knowledge we already have gained 
from that data (mechanistic models). We 
envision such mergers can and will take many 
forms. 
1. Mechanistic Model Calibration via 
Machine Learning A current challenge for 
mechanistic models is the incorporation of the 
vast amount of “omic” data into parameters. 
ML approaches could be used to identify gene 
or expression signatures that best correspond 
with given mechanistic model parameters 
utilizing cell cultures and preclinical models. 
Once initial signatures are found, correlations 
could be validated with in vivo human data. 
2. Mechanistic Model Outputs as Inputs 
to Artificial Intelligence Models A critical 
limitation for AI models is the relatively 
limited amount (both spatially and 
temporally) of data available for training. 
Mechanistic models can be used to create 
personalized extrapolations of the provided 
data for utilization in the AI models. This 
synthetic data could be used as a regularizer 
or as fully weighted training data and could 
enhance the model stability when working 
with smaller sets of data. 
3. Actionize Machine Learning 
Predictions with Mechanistic Models Static 
outputs from ML models could be leveraged 
as initial conditions in dynamic mechanistic 
models to move the ML prediction forward in 
time. If, for instance, a ML model could take 
information from the transcriptome to predict 
local concentrations of cellular constituents, 
this information could provide an initial 
condition for models of cellular interaction 
allowing the mechanistic model to better 
incorporate data from many different scales. 
4. Data Assimilation for Mechanistic 
Models utilizing Machine Learning Outputs 
Building on the previous method, if the 
appropriate data for the ML model is 
anticipated to be available for a series of 
discrete time points, such as MRIs, the ML 
model output can be used within a data 
assimilation framework to continuously 
correct predictions from mechanistic models. 
 
 
Concluding Remarks 
Science and data have always had a strong 
relationship, but in the last decade or so, the 
term data science has started taking on a 
specific meaning related to machine learning 
and artificial intelligence which ironically 
leaves behind the notion of the scientific 
method and hypothesis testing. While there is 
no doubt that the recent explosion of data 
cannot be fully exploited without such AI 
methods, mechanistic models offer a strong 
complementary, hypothesis driven, approach 
to synthesizing meaning and strengthening 
predictions that should not be ignored. This is 
particularly true in the field of mathematical 
oncology, where the data is often vast and 
deep but not representative spatially or 
temporally. Creating fundamental mergers 
between these two approaches is a critical 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – We allow at most two 
Figure 1. Illustrating the types of advances one might 
expect to see in the integration of mechanistic modeling 
into machine learning methods (and vice versa) applied to 
the case of brain cancer. Mechanistic models, e.g. 1–5, and 
machine learning, e.g. 6,7, can interact in multiple ways. 1) 
ML models can help mechanistic models make sense of 
multi-scale data to calibrate parameters, e.g. 8,9. 2) 
Mechanistic model predictions can be used as input into 
ML models to augment spatially or temporally sparse 
data, e.g. 10 3) Static outputs from ML models can be used 
as initial conditions for mechanistic models and 4) ML 
models and mechanistic models can work together via 
data assimilation to create spatially and temporally 
resolved predictions over long periods of time. 
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step to fully realizing the vision of targeted 
personalized therapy.  
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Status 
Cancer presents a complex series of systems 
problems involving intracellular dynamics, 
intercellular interactions, and extracellular 
biochemical and biophysical processes, 
embedded in a complex and continually 
changing spatial context. Although single 
laboratories can contribute important 
advances, they cannot individually solve the 
large-scale problems of cancer biology. As a 
result, consortia of experimental labs, clinical 
centers, and computational groups are 
increasingly pooling their specialized expertise 
to gain new insights into the complexity of 
cancer [11]. This pooling requires integration 
not only of heterogeneous data collected by 
different groups, but also of scientific 
hypotheses and deductive observations 
(knowledge capture), and conceptual, 
mathematical and computational models. 
Such integration is much more efficient when 
data and knowledge representations are 
standardized.  
Difficulty in finding, accessing, 
interpreting, and reusing data, knowledge, 
and models hinders collaborative cancer 
research. A lack of standardized data and 
knowledge representations, inconsistent 
metadata (e.g., to describe experimental 
protocols), technical and financial obstacles, 
and systemic cultural barriers all discourage 
sharing [12]. Modern genomics and 
proteomics demonstrate that widespread 
adoption of data standards enables faster and 
more efficient scientific progress. 
Many biological research 
communities are developing standards to 
annotate and share concepts and data. For 
example, the microarray and microscopy 
research communities are developing 
standards for sharing annotated data such as 
MGED [13] for microarrays, OMERO [14] for 
microscopy, and the National Cancer 
Institute’s “Common Data Elements for 
Cancer Research” [15].  
Currently a lack of standards impedes 
sharing of many types of mathematical 
models and computer simulations of cancer. 
While mathematical models can elegantly 
express data-driven hypotheses, their reuse 
and combination into larger-scale models 
requires (currently lacking) standardized 
representations of equations, model 
assumptions, and the rationale for parameter 
estimates. The same problems apply to 
computer simulations. 
The Systems Biology Markup 
Language (SBML) community has successfully 
developed standards to describe dynamic 
biological network models and to enable their 
translation into executable computer 
simulations [16]. The SBML standard not only 
defines mathematical concepts and syntax, 
but also allows annotation of model 
components with biological terms (e.g., 
naming genes and biological processes). Well-
constructed SBML models retain their 
underlying biological descriptions and 
associated scientific knowledge. Similar 
standards for representing multicellular data, 
knowledge and models are critical for cancer 
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research, but they are presently less 
developed. The Cell Behavior Ontology [17] 
and MultiCellDS [18] are steps in this 
direction. Standards for general knowledge 
and hypothesis representation are even less 
developed.  
Current and Future Challenges 
To maximize the value of mathematical 
models and computer simulations of cancer to 
the research community, funding agencies, 
and society, data, knowledge, models, and 
simulations should be FAIR: Findable, 
Accessible, Interpretable and Reusable [19]. 
Describing models and data using accepted 
biological nomenclature and maintaining their 
links with their underlying biological 
hypotheses would greatly facilitate finding, 
accessing and interpreting their domain and 
biological content, maximizing their value by 
capturing their embedded scientific 
knowledge for reuse. 
To enable sharing and reuse in future 
research, we must record experimental, 
clinical, and simulation data using community-
driven standards, drawing upon ontologies 
that precisely define biological terms and 
relationships. These data must include 
metadata such as descriptions of 
experimental and computational protocols 
that contextualize data and allow replication 
[12, 19].  
Beyond expressing raw data and 
models, the community must also develop 
annotations of biological hypotheses, 
observations and insights (knowledge). 
Researchers often communicate this 
information using qualitative conceptual 
“mental models” or “verbal models” that 
represent decades of expert learning. 
Machine-readable, searchable 
representations of conceptual biological 
knowledge would greatly facilitate sharing 
[12]. 
Because sharing computational 
models is largely limited to sharing source 
code with little documentation and no 
biological annotations (or worse, executables 
with no source code), simulations are often 
unreproducible [19]. Future computational 
models (and their parameter sets) must be 
biologically annotated to facilitate their reuse 
in more comprehensive multiscale 
simulations. Biological annotations would also 
make computational models more accessible 
via search engines, reducing the need for 
formal repositories and driving further reuse. 
Advances in Mathematics, Technology, or 
Data to Meet Challenges 
Enabling FAIR research requires robust 
annotation schemes for biological, clinical, 
mathematical, and computational data, 
including context, biological assumptions, and 
knowledge gained. Relationships and 
interactions between biological entities and 
processes resemble graph structures in SBML 
network models. However, “translating” 
imaging data into biological annotations will 
require machine learning approaches that 
extend beyond present-day image processing 
and feature extraction tools [12]. More 
broadly, tools and utilities must develop 
alongside standards to make standards-
compliant science simple and user-friendly, 
and to integrate it into existing experimental, 
mathematical, and computational workflows. 
We can learn from the SBML 
community's experience to develop similarly 
robust and FAIR descriptions of mathematical 
and computational models beyond SBML's 
interaction-network concepts. Representing 
spatial effects is particularly challenging. 
Projects like CellML [20] and MultiCellDS [18] 
require continued effort to grow from white 
papers to widely-adopted standards. 
Synergies are clearly possible. For example, 
descriptions of microscopy imaging data and 
multicellular simulation outputs have 
significant overlap and should admit a 
common description language. 
We also need to harmonize the 
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numerous data and model standardization 
efforts across biotech and biological 
communities. These efforts need to 
coordinate to ensure that emerging standards 
are consistent, particularly in the biological 
description of data, experiments, models, and 
knowledge. Ideally, harmonized standards 
should apply to many types of experimental 
observation (e.g., high throughput 
microscopy), and generalize from cancer to 
normal physiology and other diseases.  
Standards should be designed so that 
they support, rather than inhibit, creativity. 
Tools that make annotation and standards 
compliance easy are critical to voluntary 
adoption. Properly implemented and 
extensible standards serve as a conduit to 
communicate new ideas and allow better 
connectivity between models, tools, and data. 
Well-implemented standards provide 
value to individuals in the form of increased 
access to data, models, and tools, and greater 
impact via reuse. We must also ensure that 
standards are straightforward to implement 
across computing languages and platforms, 
particularly for scientists who focus on 
developing conceptual and mathematical 
models.  
 
Concluding Remarks 
Sharing cancer data, models, and 
knowledge using standardized formats and 
FAIR principles offers substantial benefits. 
Stable standards will encourage development 
of shared software that can import annotated 
data, design models, execute them as 
simulations, and analyze their outputs. As 
technologies such as bioprinting advance, the 
same tools could enable the direct translation 
of captured knowledge into living 
experiments. 
Technologies for sharing will help us 
create automated tools that systematically 
mine biological literature, databases, and 
knowledge repositories. Sharing technologies 
and standardized data are essential if machine 
vision and other learning approaches are to 
automate the extraction of observational 
insights from experimental, clinical, and 
simulation data [12].   
Widespread adoption of standards 
and adherence to FAIR principles will 
transform cancer research into an ecosystem 
of mutually compatible concepts, data, 
models, and tools. Such standardization will 
enable community science that exceeds the 
sum of its parts and accelerates progress in 
treating cancer. 
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Multiparametric imaging to enable 
rigorous tumor forecasting 
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Status 
While mathematical modelling of tumor 
growth dynamics has a long history, current 
approaches are limited in their practical 
applicability. There exist three main reasons 
for this. First, tumor dynamics are extremely 
complicated because of the underlying 
physical and biological processes, as well as 
the variability across individuals. Second, we 
cannot easily conduct relevant experiments; 
we can, for obvious reasons, only observe. 
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Third, the data we do observe is limited; we 
typically have few measurement points via 
anatomical imaging or biopsy.  Despite those 
formidable challenges, there is hope. Several 
imaging methods exist that can provide 
quantitative information noninvasively, in 
three dimensions, and at multiple time points.  
In particular, magnetic resonance imaging 
techniques can quantitatively characterize 
vascular properties, cellularity, pH, and pO2 
[21]. Furthermore, positron emission 
tomography can quantitatively characterize 
metabolism, proliferation, hypoxia, and 
various cell surface receptors [22].  These 
measurements can be made throughout 
therapy; thus, imaging allows models to be 
constrained with patient specific data rather 
than tabulations from the literature or animal 
studies.  
In recent years, there have been 
increasingly successful examples of 
integrating patient-specific information with 
mechanism-based mathematical models 
designed to predict the spatio-temporal 
development of cancer.  Successful efforts 
matching model predictions with clinical 
observations have been realized in cancers of 
the breast (Figure 1, [23]), kidney [24], and 
brain [25].  
 Current and Future Challenges 
If a mathematical model could faithfully 
predict the spatiotemporal evolution of an 
individual’s tumor, then patient-specific 
hypotheses could be tested in silico, thereby 
allowing the optimizing of intervention for the 
individual patient using the specific 
characteristics of their own unique situation.  
Unfortunately, this vision is quite 
disconnected from the current state-of-the-
art, and remains a grand challenge in 
mathematical oncology. Currently, the 
response of solid tumor to therapy is 
monitored by changes in tumor size as 
measured by physical exam or anatomically-
based, imaging; unfortunately, these methods 
cannot determine response as anatomical 
changes are often temporally downstream of 
underlying physiological, cellular, or molecular 
changes. Early and accurate predictions would 
enable replacing an ineffective treatment with 
an alternative regimen, thereby potentially 
improving outcomes and curtailing 
unnecessary toxicities. The development of 
mechanism-based, predictive mathematical 
models that could address this fundamental 
shortcoming in cancer care would represent, 
without question, an enormous improvement 
in the human condition. The major challenges 
to achieving this goal can be summarized by 
the following three questions: 
1. Among the enormous number of models 
covering a huge range of physical and 
biological events, which models are the “best” 
for predicting quantities of interest? 
2. How is the uncertainty in the predicted 
quantities of interest quantified and how can 
the model predictions significantly improve 
patient care? 
3. How can one access data to inform 
computational models and, at the same time, 
cope with experimental noise and errors in 
the systems used to collect and process data?   
 
 
Figure 1. A breast cancer patient was scanned by
magnetic resonance imaging at four points during
neoadjuvant therapy (NAT). The first two scans (left set
of images) are used to calibrate model parameters for
predicting response observed at the third time point. The
last two scans (right set) are used to update parameters
for predicting response observed at the time of surgery.
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Advances Needed to Meet the Challenges 
The importance of accurately predicting 
eventual patient response is difficult to 
overstate. The field of numerical weather 
prediction provides an excellent example of 
how practical, predictive oncology can be 
achieved.  Weather prediction employs 
satellites to provide a diagnosis of the state of 
the atmosphere, which is then evolved 
forward by meteorological models to provide 
a prognosis (i.e., a “forecast”) of the 
atmosphere’s future state. Similarly, imaging 
provides a diagnosis of the state of a cancer, 
which can then be evolved forward by 
mathematical tumor models to provide a 
prognosis of the tumor’s future development 
[26]. With this analogy in mind, we discuss the 
advances that must be made to address the 
three questions of the previous section.  
It is imperative that the field constructs 
mathematical models based on the 
established principles of physics and cancer 
[27]. While phenomenological models can 
provide practical advances for predictive 
oncology (e.g., the linear quadratic model of 
radiobiology [28]), they are fundamentally 
limited in their ability to describe the 
underlying biology and, therefore, the precise 
effects of any therapeutic intervention. 
Unfortunately, this has proved to be a terribly 
difficult undertaking as we do not yet have 
the F = ma of cancer.  In lieu of this 
fundamental relation, we have advocated for 
developing families of models (reminiscent of 
the approach used in weather modelling), 
each with its own set of biological and 
physical assumptions [26, 29]. These models 
are then calibrated with rationally selected, 
patient-specific data, before being subjected 
to a Bayesian methodology that both selects 
the optimal model and then validates its 
ability to accurately predict the 
spatiotemporal development of an individual 
patient’s tumor.   
The sentiment that we are “swimming in 
data” is often expressed, but it is a 
tremendous oversimplification. While it is true 
that there are volumes of clinical data 
available, it is not of the kind that is readily 
integrated into mechanism-based models. We 
may be swimming in data, but we are in the 
wrong pool. Advances in biomedical imaging 
are now providing us with the appropriate 
tools to quantitatively characterize cellular, 
molecular, and physiological processes that 
can constrain the next generation of 
predictive models.  
 
Concluding Remarks 
It must be stressed that building data-
informed, mechanism-based mathematical 
models of cancer is a fundamentally different 
approach than relying only on “big data" [30].  
This is not to dispute the fact that statistical 
inference is of critical importance; but rather, 
by its very nature it is based on statistical 
properties of large populations in which 
conditions that prevail in specific individuals 
are hard to detect.  That is, the “big data-
only” approach cannot account for subtle 
changes in the individual patient—indeed, the 
very characteristics that make us individuals—
over an extended time. It is critical to unite 
such population-based statistical data with 
patient-specific measurements and with 
patient-specific mathematical models that can 
predict patient-specific changes associated 
with cancer initiation, progression, and 
response to therapy. This transformation is 
inevitable. 
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Cancer screening and early 
detection with modeling 
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Status 
Cancer screening aims to detect neoplastic 
changes early for curative intervention. 
Current programmes, however, suffer from 
both overdiagnosis of benign lesions and 
underdiagnosis of dangerous lesions missed 
by screening [31]. Consequently, 
improvement in screening success is an 
important health policy research area, and 
one primed for quantitative assessment. In 
this Roadmap article we argue that 
mathematical modeling of tumor evolution 
will underpin radical improvement in the 
effectiveness of screening and surveillance. 
 For clarity within a varied literature, 
the term cancer screening refers to initial 
testing for the presence of a specified 
neoplastic change of interest in the body (e.g., 
detection of premalignant or malignant 
lesions). Subsequent tests that are offered 
after an initial screening diagnosis are defined 
as surveillance screens. A biomarker is a 
measurable, objective indication of a 
biological state (e.g., aneuploidy or tumor 
size) associated with relevant preclinical 
disease states potentially before symptoms 
develop.  
The length of time between the early 
detection of a preclinical state and the future 
clinical detection is called lead time, which 
depends on the nature of the biomarker 
measured. If the age at completion of lead 
time surpasses patient lifetime, this patient 
will be considered an overdiagnosed case for 
that cancer. Lastly, risk stratification refers to 
prognostic subgrouping offered to patient 
groups based on screen outcome.  
Currently, screening design uses data 
from epidemiological studies but does not 
typically consider tumor evolution, which 
ultimately determines disease development 
timescales. From a biological perspective, 
early detection of biomarkers that alert us to 
cellular changes along the path to cancer (e.g., 
premalignant metaplasia detected in biopsy 
sample histology, or circulating tumor DNA 
present in liquid biopsies) is the clinical 
manifestation of field cancerization, wherein 
groups of cells have acquired some but not all 
of the phenotypes necessary for clinical 
malignancy [32]. If we determine the pattern 
and pace at which normal cells become 
cancerized in their microenvironments, we 
can utilize multiscale data within 
mathematical models of carcinogenesis to 
evaluate and predict the efficacy of screening 
strategies for early detection in silico (Fig 1).    
The impact of this research will be to 
develop novel methodology capable of 1) 
utilizing screen data to assay the carcinogenic 
process in vivo, and 2) robustly assessing and 
refining screening practices using mechanistic 
forecasting to improve early detection and 
personalize clinical recommendations.  
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Current and Future Challenges 
Current screening prevents cancer deaths but 
there are many areas for improvement. Below 
we discuss a few main challenges faced. 
1. Defining success and introducing bias 
To measure the efficacy of screening, 
investigators may perform randomized 
control trials (RCT) to compute relative risks of 
endpoints such as cancer incidence and 
mortality between screened and unscreened 
populations [31]. Although intended to reduce 
biases, these studies are not designed to 
predict long-term trade-offs in costs vs. 
benefits between alternative 
screening/lifelong surveillance regimens, 
which instead require decision modeling [33-
39]. The choice of metric for quantifying early 
detection-associated costs (e.g., decreased 
patient quality of life or burden to the 
healthcare system per overdiagnosed case) vs. 
benefits (e.g., life-years gained or cancer 
precursor eradication per screen) will vary 
cost-effectiveness results.  
2. Choosing an appropriate computational 
model  
Model selection for the established 
outcome must capture the essential 
features of disease progression from birth 
to death. These might include 
epidemiological features such as patient 
smoking history [33] and sampling modality 
such as tissue [34] or blood [35] biopsies. 
Importantly, the relationship between 
biomarker level and time (Fbiomarker, Fig 1) is 
often sensitive to clinically unobservable 
events, such as metastasis initiation [36] 
and false positive diagnoses [37], 
potentially confounding reports from 
medical exams and contributing to 
inaccuracy of mathematical formulation. 
3. Handling stratification and heterogeneity 
Based on biomarkers measured from screens, 
patients are stratified into ‘low’ and ‘high’ risk 
groups. Prognostic cut-offs between groups 
are ultimately arbitrary and can be subject to 
medical discretion. Two common issues with 
this practice are that studies rarely consider 
time-dependent implications (e.g., a high-risk 
mutated cell may not survive long enough to 
initiate tumorigenesis) and most rely on a 
small subset of risk factors measured at a 
single time point rather than a holistic view of 
diverse patient background (e.g., family 
history of cancer, lifestyle, immune system’s 
innate ability to eliminate mutated cells, 
adverse mutations). Moreover, the challenge 
is to accurately characterize the unique 
evolutionary trajectories of individuals (Fig 
1A), while still recommending useful 
screening programs that capture average 
population behavior (Fig 1B). 
4. Testing and performing model validation  
New technologies for early detection are 
rapidly developing, but it remains costly to 
obtain large, longitudinal cohort follow-up 
data to robustly assess outcomes and validate 
Figure 1.  A) Evolutionary trajectories of slow versus fast carcinogenesis 
correspond to longer versus shorter lead times for potential clinical 
intervention, respectively. B) Screening programme design aims to 
maximise positive biomarker yield in an average at-risk population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – We allow at most two figures that 
are roughly the size of this box. 
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screening recommendations in those with an 
adverse biomarker state; such clinical 
evidence will be required before altering the 
existing screening regimens.  
 
Advances in Mathematics, Technology, or 
Data to Meet Challenges 
1. Collecting population data for research use 
National health institutes are increasing 
support of early detection studies obtained 
from prospective cohort and large-scale 
population screening, which will better inform 
parameters used in modeling such as disease 
regression rates and more subjective 
measures like quality-adjusted life-years used 
in economic evaluations. 
2. Mathematical developments 
Mathematical modeling (stochastic processes, 
evolutionary theory, dynamical systems, 
differential equations) is a framework that can 
help us to rigorously answer the questions of 
‘when’ to screen individuals for cancer 
indications, and ‘who’ will benefit most from 
particular surveillance regimes and clinical 
intervention.  There is a clear need for novel 
methods to combine models with classical 
biostatistics commonly used in cancer risk 
stratification studies for clinical translation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three current methodologies for assessing 
cancer screening with modeling are shown in 
Fig 2. These include Markov chains for natural 
history of disease transition [33,37,38], 
biologically-based models that can 
incorporate evolutionary dynamics like clonal 
expansions and biomarker shedding in diverse 
lesions [33-36,39], and biological event timing 
models that infer critical genetic events 
during carcinogenesis [40]. Moreover, 
biologically-based models could inform the 
transition probabilities of the Markov 
approach. The aim of all of these models is to 
quantify long latency periods of 
premalignancy on a patient’s forecasted 
evolutionary trajectory. These periods provide 
a window for therapeutic intervention when 
detected during effectively-timed screens.  
3. Modern technologies for sensitive and 
specific early detection biomarkers  
Rapid advancements in multi-omic and optical 
imaging technologies allows for the diagnoses 
of precancerous and early cancer lesions at 
higher resolution and at decreasing cost to 
the healthcare system. This will provide 
researchers with better understanding of 
patient-specific disease evolution, and 
ultimately result in personalized prevention 
efforts becoming a clinical reality. Taking a 
holistic view and studying disease evolution at 
adequate power will require huge amounts of 
well-annotated patient data, but with 
digitization of medical records and large 
population cohorts currently undergoing 
follow-up, we envisage this may be feasible 
within the next 30 years. 
 
 
Figure 2.  Three models of carcinogenesis to evaluate 
screening. (A) Natural history models may also explicitly 
include misdiagnoses into transition rates. (B) Biological 
models can incorporate growth rates initiated by tumor 
suppressor gene inactivation (e.g., APC in colorectal 
adenomas [9]). (C) Inferred biological event models can 
include alternative pathways such as known germline 
mutations (e.g., VHL in patients with von Hippel-Lindau 
disease [10]). 
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4. Performing virtual trials in silico for rigorous 
model selection and testing 
 Well-calibrated mathematical models provide 
a cost-effective, ethical means for simulating 
virtual cohorts of patient outcomes to judge 
the effectiveness of a screening/surveillance 
regime both across a population and in 
individuals. Bayesian approaches and deep 
learning of large clinical datasets will also 
enhance statistical inference of unobserved 
events that drive carcinogenesis timing; such 
modeling will be necessary in future early 
detection research as it is not technically 
feasible to measure many aspects of 
tumorigenesis (such as single progenitor cell 
initiation) in the patient cohort itself. 
Moreover, this dynamic, computational 
approach is a straightforward method to 
continuously test and recommend 
modifications to screening/surveillance 
guidelines (e.g., to reflect subsequent 
technological advances in endoscopic optical 
imaging), as opposed to the current situation 
wherein such guidelines are updated on 
average once per decade.  
 
Concluding Remarks 
There is exciting potential for mathematical 
modeling in addressing the challenges of 
cancer early detection, alongside 
developments in biomarker discovery and 
validation. Modeling cancer screening will 
allow researchers to examine the underlying 
cause of the vast inter- and intra-patient 
heterogeneity we currently observe clinically 
during disease progression in a robust and 
unbiased way. It will be possible to create 
explicit formulations for the dynamics of 
biomarker changes in the body and to 
formulate quantitative functions for screening 
efficiency in order to optimize cancer 
screening and surveillance scheduling.  
In reality, all cancers form from a 
series of evolutionary changes that may be 
detectable (and potentially preventable) if we 
anticipate and seek such changes during 
screening, and track them during surveillance 
to direct clinical action. In our increasingly 
integrated world, patients, doctors, policy-
makers, and mathematical modelers will be 
required to engage in interdisciplinary science 
efforts to best answer questions about how to 
beat cancer early.  
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Status 
The development and progression of cancer is 
driven in part by evolutionary processes 
within the underlying tissue cell populations. 
Cells that are subject to homeostatic 
regulation in healthy tissue acquire mutations 
that can alter the properties of the affected 
cell.  Many such mutations can lead to a 
selective disadvantage while others do not 
change the fitness of the cell or confer a 
selective advantage. Accumulation of one or 
more such driver (advantageous) mutations 
can allow the cells to escape homeostatic 
regulation and to proliferate out of control. 
These clonally expanding cells can in turn 
accumulate further mutations that result in 
increases in heterogeneity in the cell 
population and in further progression of the 
tumor. Such evolutionary processes are not 
only crucial for the disease development, but 
can also contribute to resistance against 
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cancer therapies. It is therefore crucial to gain 
understanding of both the evolutionary 
principles according to which tumors 
progress, and the mechanisms by which 
treatment resistance evolves. 
 
Mathematical models form an integral part in 
the analysis of evolutionary dynamics in 
general, and the same applies to evolutionary 
dynamics in the context of tumors [41, 42]. 
Mathematical and computational work has 
contributed insights both into aspects of 
tumor initiation and progression, and into the 
principles of resistance evolution [43]. 
Important measures that have been 
investigated include the probability that 
mutants resistant against a given treatment 
regime exist in the tumor cell population at 
the time when treatment is started; the 
expected number of mutants that are present 
at the time when treatment is started; the 
probability that mutants with certain 
characteristics become fixed in healthy tissue 
or an emerging tumor; the time it takes for 
mutants to rise towards a certain threshold 
level, etc.  In the context of specific tumors, it 
has been possible to measure some of the 
main parameters underlying such models for 
individual patients. One example is chronic 
lymphocytic leukemia [44]. Division and death 
rates have been measured by administering 
deuterated water to patients, radiological 
imaging has been used to estimate the total 
tissue tumor burden, and model fitting to 
clinical data has been used to estimate kinetic 
parameters underlying treatment responses. 
With the knowledge of such patient-specific 
parameters, the mathematical modeling 
approaches can in principle be used to make 
individualized predictions about treatment 
outcomes, such as the time to resistance-
induced relapse against targeted therapies 
[45]. They can further be used to explore 
alternative treatment options with the aim to 
prolong the duration of tumor control.  
Current and Future Challenges 
Much of the work described so far has been 
performed under the assumption that there is 
no spatial structure in the cell population, i.e. 
that cells mix well with each other. This might 
be a reasonable approximation for some 
leukemias, but is an unrealistic assumption for 
solid tumors, which are characterized by 
complex spatial structures. A variety of spatial 
computational models of tumors have been 
developed to study different questions, e.g. 
[46], notably mechanistic models of tumor 
growth and vascularization have been 
successful. Many aspects of the evolutionary 
dynamics of mutant populations in spatial 
settings, however, remain poorly understood. 
Interestingly, analyses of spatial evolutionary 
processes performed so far indicate that the 
dynamics can be significantly affected by 
spatial structures, often in complex ways. An 
example is the process of fitness valley 
crossing, where an advantageous phenotype 
requires the accumulation of two (or more) 
separate mutations, each of which is 
individually deleterious or neutral. Such 
evolutionary pathways have been 
documented to occur in the context of many 
cancers. An example is the inactivation of 
tumor suppressor genes, such as the APC 
gene in colorectal cancer, where both copies 
of the gene have to lose function for the cell 
to become advantageous.  It turns out that 
the evolutionary timing of fitness valley 
crossing depends on the exact assumptions on 
the spatial dynamics [47] (Figure 1). 
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In the spatial Moran process model that 
assumes constant cell populations, spatial 
interactions were found to accelerate the rate 
of fitness valley crossing. By contrast, in 
contact processes that do not assume 
constant cell populations, the rate of fitness 
valley crossing could be accelerated or 
delayed, and there could even be an optimal 
degree of mixing that maximizes the rate of 
evolution.  
 
Studies of single mutant dynamics in spatially 
structured cell populations have also shown 
that basic mutant dynamics in space are 
different compared to well-mixed scenarios 
[48]. The fate of mutants can depend on the 
timing and the spatial location of mutant 
emergence. Mutants that are generated 
relatively early and at the surface of an 
expanding spatial cluster of cells can grow to 
relatively large numbers (also referred to as 
“jackpot” mutations). On the other hand, 
mutants can become surrounded and encased 
by wild-type cells, which limits their growth 
and introduces and element of competition 
between mutant and wild-type cells, even 
though the tumor mass is characterized by 
unbounded growth. A better understanding of 
how evolutionary processes contribute to 
cancer development in such settings is crucial 
for improving therapies. It is especially 
important is to gain understanding of how 
mutants clones defined by different 
susceptibilities to specific therapies develop in 
such spatial scenarios, both in the presence 
and in the absence of treatment. 
 
Advances in Mathematics, Technology, or 
Data to Meet Challenges 
As more information is obtained about the 
spatial evolutionary dynamics of tumors, both 
experimentally and theoretically, spatial 
computational models will increasingly form 
the basis for simulating disease progression 
and therapy outcome for specific scenarios 
and individual patients. In contrast to 
investigating basic principles of evolutionary 
dynamics, however, these applied questions 
will require the simulation of tumor growth 
and evolution at realistically large population 
sizes. Because this brings with it significant 
computational costs, the simulation of cell 
populations that reach sizes between 1010 and 
1013 cells becomes unfeasible. The problem 
lies in the fact that while the overall tumor 
population size is very large, mutant cell 
populations exist initially at very small 
numbers, which requires stochastic 
simulations. The time step in stochastic 
simulation algorithms decreases as the overall 
population becomes large, thus rendering 
such computer simulations impractically slow. 
One way in which this problem has been dealt 
with is to assume smaller cell populations and 
higher mutation rates, hypothesizing that the 
dynamics scale in realistic ways. It is, however, 
currently unclear whether this holds true.  
Figure 1: Schematic illustrating the different effects spatial 
restriction can have on the waiting time until a fitness valley is 
crossed, in the Moran Process and the contact process. 
Nearest neighbor interactions represent the strictest degrees of 
spatial restriction, while mass action corresponds to perfect 
mixing of cells. 
Page 18 of 46AUTHOR SUBMITTED MANUSCRIPT - PB-100995.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
a
u
cri
pt
Phys. Biol. ## (2019) ######  Roadmap 
Therefore, to be able to simulate and predict 
tumor development and treatments at 
realistically large population sizes and at 
realistically small mutation rates, novel 
computational methodologies are required.  
To this end, a modeling approach has been 
proposed which assumes that the tumor 
consists of discrete microlesions; cells can 
migrate from microlesions to establish new 
ones, which can all grow over time, and new 
driver mutations can be generated [49]. From 
this model, the average behavior can be 
obtained analytically, which allows simulation 
of tumor dynamics and evolution at large 
sizes. In order to capture the stochastic 
dynamics of various mutant types, however, 
methodologies need to be developed that 
allow the stochastic description of small 
mutant clones in a spatial setting in realistic 
time frames. Deterministic partial differential 
equation approximations of such spatial, 
stochastic processes generally do not yield 
accurate time series. In the context of mixed 
populations (where stochastic dynamics are 
simulated e.g. with Gillespie’s method), novel 
computational approaches have been 
developed (e.g. the Next Reaction Method 
and Tau-Leaping methods), which try to 
address these difficulties. There is also an 
important push in the development of hybrid 
stochastic-deterministic approaches, where 
small populations are handled stochastically, 
while larger populations are described 
deterministically.  Such approaches have been 
typically employed in the field of physical 
chemistry, but have not significantly 
penetrated the studies of population 
dynamics and evolution, presumably because 
they can rely on theoretical concepts (e.g. 
Langevin’s equation), which are not very 
common in these fields. At the same time, 
such approaches would be very useful for the 
field of mathematical oncology, as 
demonstrated by a recent study [50]. 
Application of such methodology to spatial 
dynamics, however, is a complicated 
extension, the development of which will be 
as challenging as it is important. The ability to 
simulate spatial tumor evolution at realistic 
population sizes and mutation rates will be 
central to the development of clinically 
applicable computational models of tumor 
evolution, which can be used for the 
personalization of therapy regimes.  
 
Concluding Remarks 
The importance of spatial genetic 
heterogeneity in tumors has penetrated 
clinical and experimental cancer research. In 
various cancers, data indicate that a tumor 
mass can consist of regions that are 
genetically distinct and that contain different 
mutants that can influence the susceptibility 
of these cell clones / spatial regions to 
therapies. The emerging biological details 
about evolutionary patterns in spatially 
structured tumors will allow appropriate 
computational models to make more accurate 
and clinically relevant predictions regarding 
disease course and treatment outcome, and 
the availability of efficient computational 
methodologies will be of central importance 
in this respect.    
 
A single-cell topological view of 
cancer heterogeneity and evolution 
Luis Aparicio*, Mykola Bordyuh* and 
Raul Rabadan. Department of Systems 
Biology, Columbia University 
*These authors contributed equally to this work. 
 
Status 
A tumour is a dynamic disease of the cell that, 
through alterations in its genome and 
epigenome, leads to its uncontrolled 
proliferation.  Tumours are found to vary 
dramatically across patients (inter-tumour 
heterogeneity) and across cells within a 
tumour (intra-tumour heterogeneity). 
Heterogeneity has been found to be a major 
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factor in cell adaptation driving spread and 
response to therapy [1].  
 
With the advent of high throughput 
sequencing [2], there has been a dramatic 
development in the characterization of inter-
tumour diversity. Large scale efforts, like The 
Cancer Genome Atlas or the International 
Cancer Genome Consortium, have portraited 
the molecular make up of thousands of 
tumours generating diverse large-scale 
biological datasets. The need to extract useful 
biological and clinical knowledge from these 
efforts have highlighted the necessity for new 
mathematical and computational methods to 
analyse and integrate them.  
 
The past few years have witnessed the further 
development of a variety of techniques 
enabling single-cell molecular measurements, 
including sequencing the DNA of single cells, 
or measuring their mRNA, methylation, 
chromatin state or protein levels [3, 4]. Single-
cell RNA sequencing constitutes a powerful 
technology to address the problem of intra-
tumor heterogeneity, enabling the 
quantification of transcriptome landscapes at 
single-cell resolution, and providing a tool to 
observe the dynamics of tumor evolution.   
However, single-cell sequencing data comes 
with some unique analytical challenges. These 
challenges can be appreciated in dynamic 
biological phenomena like cell differentiation 
or tumor evolution, continuous processes 
where traditional clustering methods may not 
be suitable. While clustering tries to split data 
into seemingly distinct sets, the analysis of 
dynamic processes needs methods that are 
able to capture the continuous relation 
between cellular states. Topology is a branch 
of mathematics that studies continuous 
transformations of geometrical objects. 
Topological data analysis (TDA) adapts 
techniques of topology to extract information 
from the geometric and topological data 
structure. This makes TDA amenable to deal 
with continuous data structures and 
therefore, to analyze single-cell data of 
dynamic biological processes, including 
cancers.  
 
 
 
Current and Future Challenges 
Ambitious large-scale single-cell projects aim 
to provide atlases of millions of cells pushing 
the analysis into the paradigmatic “Big-Data”, 
high-dimensional scenario. The variety of 
single-cell platforms and associated unique 
technological challenges bring an additional 
layer of complexity into the analysis. 
Associated technological problems vary across 
platforms and include drop-out effects, big 
sparsity of the data (on the order of 90% of 
the inputs) and noisy biological or 
technological variability in gene expression 
(typically, around 99% of the variability is 
associated with the noise). On the other hand, 
the discovery of rare subpopulations and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  A) Simulation of a longitudinal single-cell analysis with datasets at different 
timepoints. Different colours represent different cell types or states. In the down side, 
a TDA representation. B) Comparison of TDA and traditional algorithms for 
dimensional reduction, as Multidimensional Scaling (MDS), Principal component 
analysis (PCA) and t-distributed Stochastic Neighbor Embedding (t-SNE). 
.   
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transitional cell states, which may amount 
only to a dozen per experiment, present 
unique computational challenges. Here, we 
would like to emphasize two mathematical 
properties of the underlying processes, that 
are useful when analyzing single-cell data [5]:  
The continuity, associated with cell 
differentiation and the locality property, 
important in identification of different 
branches of cell differentiation and small 
subpopulations. 
 
In Figure 1, we highlight these two important 
attributes and principles. In Figure 1A, we 
show the schematics of cell differentiation at 
different timepoints. Traditional clustering 
techniques only provide limited information 
about well-defined cell states, failing to 
explore continuous nature of cell 
differentiation processes. Topological 
representation of the processes, depicted in 
Figure 1 A (bottom), captures both continuous 
structure of the process and well-defined 
states of cells, associated with clusters. In 
Figure 1B, we illustrate the locality property, 
important in preserving differences in cell 
populations, that otherwise are disregarded in 
lower dimensions. If locality is not preserved, 
close cell types in high-dimensional spaces, 
but biologically distinct can be artifactually 
misrepresented as close (even identical) 
points in the reduced space. As an example 
(see Figure 1B), we took a 3D “Trefoil” curve, 
where every point is distinct in the original 
space. Low-dimensional representations, as 
MDS, PCA and t-SNE algorithm among many 
others, tend to create artifacts, by breaking 
the continuity or failing to separate distinct 
points. Topological representation respects 
both continuity and locality of every point. 
 
 
 
 
Advances in Mathematics, Technology, or 
Data to Meet Challenges 
In the past decade, TDA has emerged as a new 
discipline at the interface between machine 
learning and algebraic topology. The goal of 
TDA is to extract and represent information 
about the shape of data. One can think of 
single-cell data as points (cells) in a high-
dimensional space, where the dimensions 
correspond to the number of features 
(typically genes). Most constructions of TDA 
consist of replacing the original space by a 
mathematical object called simplicial complex, 
that captures topological features. Simplicial 
complexes can be seen as generalizations of 
networks (see Figure 1A and Figure 2).  
 
One of these properties is the skeleton of the 
space or Reeb space which informs us about 
the number of connected components in the 
space or how many holes of different 
dimensions exist. Mapper [6] is an algorithm 
based on TDA which constructs simplicial 
complexes as approximations to Reeb spaces. 
The result, when applied to single-cell data, is 
a network where nodes represent sets of cells 
with similar global transcriptional profiles, and 
edges connect nodes that have at least one 
cell in common. In Figure 2, we show an 
example of a topological representation for 
single-cell RNA sequencing of glioblastoma 
corresponding to a patient sequenced in [7].  
In this case, TDA is not only able to 
disentangle different tumor and stromal cell 
populations (Figure 2A), but also to capture 
intra-tumor heterogeneity. Figures 2C and E 
show a different distribution of astrocytes and 
oligodendrocytes within the tumor 
population. Interestingly, from panels B and D 
one can extract a certain correlation between 
the neural progenitor signature and the more 
proliferative cells and also more astrocyte-like 
markers. 
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Concluding Remarks 
Single-cell technologies are a powerful tool to 
study fundamental aspects of cancer biology 
at an unprecedented resolution. This is 
generating an increasing explosion of 
molecular data and as a consequence, the 
necessity of new mathematical methods to 
analyse it. On the other hand, the intrinsic 
features of single-cell datasets constitute a 
challenge for traditional methods of analysis 
based on combinatorics and clustering. TDA is 
a modern mathematical set of tools which has 
a potential to overcome these difficulties. 
Remarkably, algorithms based on TDA 
preserve locality and are able to capture the 
continuous nature of the biological 
phenomena that are analysed at a single-cell 
level [8, 9, 10]. This is crucial to understand 
better tumour progression and evolution. 
Future work applying TDA techniques may 
shed light on key questions in cancer studies 
like the structure and information contained 
in the tumour heterogeneity.   
 
 
Acknowledgements 
The authors would like to thank NIH for their 
support through the grants: U54-CA193313, 
U54-CA20997, R01-CA185486, R01-CA179044.  
Metabolism in Cancer Progression 
Stacey D. Finley 
Department of Biomedical Engineering, 
University of Southern California, Los Angeles, 
CA 90089, USA 
 
Status 
Altered metabolism is a hallmark of cancer 
that enables cancer cells to meet the high 
energetic burden required to support their 
increased proliferation. Such metabolic 
reprogramming mediates cancer progression, 
influences treatment efficacy, and contributes 
to drug resistance. Thus, it is imperative to 
better understand tumor metabolism, 
including metabolic networks in cancer cells 
specifically, and in other cells that comprise 
the tumor microenvironment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – We allow at most two figures that are 
roughly the size of this box. 
Figure 2. A) A topological representation of a glioblastoma RNAseq single-
cell dataset shows diverse stromal/tumour populations. The expression of 
specific genes shows similarity with known cell populations:  B) 
representation of MKI67 expression, C) oligodendrocyte genes expression, 
D) neural progenitor expression, and E) astrocyte genes expression. 
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Systems biology approaches, including 
computational modeling, are needed to 
obtain a global understanding of the 
interconnected metabolites, enzymes, and 
regulatory mechanisms that characterize 
cellular metabolism. Systems biology methods 
allow controlled exploration of the roles of 
multiple cell types, molecular species, and 
biochemical reactions in cellular metabolism. 
Such approaches focus on how individual 
components of biological systems contribute 
to system function and behavior, facilitate a 
deeper understanding of complex biological 
processes, and provide opportunities to 
develop new hypotheses and interventions.  
There is a substantial and productive 
history of applying computational modeling to 
study cancer, from initiation through 
metastasis [61]. This work demonstrates that 
computational models, refined by 
experimental results can reveal effective 
treatment strategies and provide unexpected 
predictive insights. In fact, systems biology 
modeling complements pre-clinical and 
clinical studies of tumor metabolism. 
Specifically, systems biology models of cancer 
metabolism [62] provide quantitative insight 
into the dynamics of metabolic pathways, are 
useful in investigating the metabolic 
mechanisms driving the cellular phenotype, 
and have helped identify potential 
therapeutic strategies. Thus, systems biology 
approaches provide new insights into 
metabolism and can lead to novel therapeutic 
strategies. When constructed and validated 
using experimental measurements, systems 
biology models can be used to perform in 
silico experiments to predict the effects of 
perturbing the metabolic network. In this way, 
the models are a valuable alternative to wet 
experiments that can be expensive and time-
consuming.  
 
 
 
Current and Future Challenges 
Many published metabolic modeling 
techniques have focused on constraint-based 
approaches in which certain physical, 
chemical, or biological constraints are applied 
to predict the metabolic phenotypes. These 
are time-invariant stoichiometric models that 
predict reaction fluxes, which remain difficult 
to measure experimentally at the systems-
level. Genome-scale metabolic models have 
been constructed to explore the 
interconnected metabolic pathways 
documented to occur in an organism, 
including cancer-specific models [63]. Such 
models provide insight into how particular 
oncogenes influence metabolism, and they 
help identify specific drug targets and 
biomarkers. However, constraint-based 
models are static and fail to capture the 
kinetic aspects in the system or time-varying 
heterogeneities that arise due to 
environmental fluctuations. Additionally, 
ongoing work is aimed at integrating high-
throughput omics data into constraint-based 
models for a more comprehensive view of the 
metabolic landscape. Overall, constraint-
based models are widely used, and they 
contribute to our understanding of the role of 
metabolism in cancer progression. 
Kinetic modeling is an alternative to 
constraint-based modeling. When considering 
processes that are inherently transient, such 
as the effects of reprogramming of cancer 
metabolism, kinetic modeling is required to 
understand the dynamic relationships 
between metabolic fluxes, metabolite 
concentrations, and microenvironmental 
conditions. Therefore, models that represent 
the metabolic pathways using a system of 
nonlinear ordinary differential equations are 
useful. These kinetic models provide a 
mechanistic description of the transient 
dynamics of the system and have been used 
to identify key enzymes associated with tumor 
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growth and malignancy and predicted the 
effects of targeting those enzymes [64].  
  Though highly valuable, kinetic 
modeling also has some drawbacks. One 
limitation is that these models require many 
kinetic parameters in order to accurately 
characterize the reaction rates. This can be 
overcome by fitting the model to quantitative 
experimental data and estimating the 
parameter values needed to best fit the data. 
Another limitation is that while these models 
predict the dynamics of intracellular 
processes, they rarely account for 
downstream effects that occur at the cellular 
and tissue level.  
Indeed, multi-scale modeling is a 
challenge impeding the successful application 
of systems biology approaches to address 
clinically relevant questions related to cancer 
metabolism. There are two aspects to this 
challenge. The first is a need for robust 
computational tools to link mechanistically 
detailed, dynamic models of intracellular 
metabolism to tumor growth. Second, there is 
a need for multi-scale models that link a 
detailed metabolic network model to cell 
proliferation/apoptosis and account for the 
heterogeneous, multi-cellular tumor 
microenvironment. It is well established that 
the internal dynamics of metabolism directly 
influence cancer progression. In addition 
tumor-stromal interactions play an important 
role in drug resistance. However, there is a 
lack of spatiotemporal models that address 
these critical aspects of cancer metabolism. 
 
Advances in Science and Technology to Meet 
Challenges 
The key to advancing systems biology models 
of cancer metabolism is to take advantage of 
existing computational tools for performing 
multi-cellular simulations and link them with 
detailed models of intracellular metabolism 
with cell- and tissue-level dynamics. There are 
many computational models of cancer cell 
growth and progression, but few simulate 
how the dynamics of intracellular metabolism 
drives tumor growth. Our recent work links a 
detailed kinetic model of intracellular 
metabolism to population-level cancer cell 
proliferation [64] but does not simulate the 
dynamics of individual cells. Ghadiri and 
coworkers integrate a constraint-based model 
with an agent-based model of tumor [65]; 
however, this model does not evaluate the 
metabolic fluxes within each cell as time 
progresses.  
Some computational models of cancer 
predict metabolic interactions between tumor 
cells. In one example, Robertson-Tessi et al. 
incorporate a simplified metabolic model with 
angiogenesis and tumor growth and predict 
treatment outcome [66]. They developed a 
hybrid continuum/agent-based model in 
which glucose and oxygen are metabolized 
inside of the cell and directly influence cell 
growth. However, these models rarely 
account for the interactions and 
dependencies between cancer cells and other 
cells in the tumor microenvironment. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – We allow at most two figures that 
are roughly the size of this box. 
Figure 1.  Schematic of relevant systems investigated when 
modelling cancer metabolism. 
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Moreover, these models lump together 
several metabolic reactions and thus cannot 
predict how targeting specific metabolic 
enzymes influences cell growth. 
Overall, there is a clear gap in the 
application of multi-cellular modeling 
combined with mechanistically detailed 
models, particularly in the context of cancer 
metabolism. Some tools exist that enable 
computationally intensive simulations of 
multi-cellular environments; however, future 
work is needed to combine these tools with 
computational models of metabolism reaction 
networks. We highlight two particular tools: 
CompuCell3D and PhysiCell. 
• CompuCell3D employs lattice-based 
Glazier-Graner-Hogeweg (GGH) stochastic 
modeling of generalized cells to simulate 
tissue-scale behavior [67]. The generalized 
cell’s behavior (such as proliferation, an 
increase in volume, migration, and cell-cell 
adhesion) is driven by its effective energy. 
The probability that a behavior is 
performed depends on how that behavior 
changes the cell’s effective energy (i.e., 
whether the potential behavior increase or 
decrease the energy). Behaviors that lower 
the cell’s effective energy are preferred. 
CompuCell3D has been applied in many 
instances, including incorporating 
intracellular signaling dynamics that 
influence the cells’ behavior [68]. 
• PhysiCell implements off-lattice cell agents 
to model multicellular systems within a 
biochemical microenvironment [69]. Cell 
agents interact via direct physical contact 
or by exchanging diffusible biochemical 
signals. This tool has been applied to 
model up to 106 cells in tissue volumes of 
~10 mm3. In addition, PhysiCell makes it 
possible to link intracellular networks with 
cell behavior. For example, a Boolean 
model of cell signaling has been embedded 
within each cell to simulate the effects of 
breast cancer treatment [70]. 
 
Concluding Remarks 
With multi-scale, multi-cellular models in 
hand, it would be possible to predict the 
effects of molecularly targeted metabolism-
based therapies on cancer cells, neighboring 
cells in the tumor, and overall growth of the 
tumor tissue. Such multi-scale models that 
include detailed metabolic reactions in 
combination with cell-cell interactions can be 
used to identify novel cancer treatment 
strategies, serving as a framework to 
hypothesize optimal drug combinations and 
treatment protocols. We can draw upon work 
that successfully integrates models of 
intracellular signaling models with the cell-
level response. And in the future, multi-scale 
models that incorporate both signaling and 
metabolism networks can even be combined. 
In conclusion, detailed modeling of cellular 
metabolism is a clinically relevant application 
of systems biology modeling that has the 
potential to significantly impact cancer 
treatment. 
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Status 
Radiation therapy (RT) is the single most 
commonly used cancer treatment. More than 
50% of patients receive radiation at some 
point in their cancer care, either as curative 
monotherapy, in combination with surgery, 
chemotherapy, or immunotherapy, or as 
palliative therapy. Current RT practice is based 
on maximum tolerated dose (MTD) concepts 
independent of patient-specific biology. 
Treatment protocols have been derived from 
average outcomes of long-term empirical 
practices or large clinical trials, and continue 
because they have produced reasonable 
outcomes.  Despite a long history of medical 
physics and physical concepts centered 
around radiation dose delivery technology 
and safety, few inroads have been made to 
synergize quantitative approaches with 
radiation biology and radiation oncology 
methodologies to optimize RT and treatment 
personalization. Integrating mathematical 
modelling with radiation oncology may have 
an immediate impact for a large number of 
patients, and help revolutionize how we 
conceive of and clinically prescribe 
radiotherapy in the precision medicine era.  
 
Current and Future Challenges 
RT is the most successful treatment in cancer 
care that can be given with the intent to cure, 
as palliative therapy, or potentially with the 
intent to convert the tumor into an in situ 
vaccine [71]. Whilst a wealth of radiation 
biology data has been, and continues to be 
collected, few biological concepts have 
impacted clinical radiation oncology relative 
to physical conformality of dose. Historically, 
dose-escalation trials have focused on 
increasing log cell kill with acceptable 
toxicities to provide as much loco-regional 
control as possible. In current RT practice, the 
treatment protocol parameters (total dose 
and dose fractionation) are prescribed a priori 
based on tumor type, disease stage, nodal 
status, and metastatic burden [72]. Whilst 
cancer is reminiscent of a complex dynamic 
adaptive system that may be best understood 
by perturbing it, to date no concerted efforts 
have focused on collecting and evaluating 
longitudinal tumor states to personalize RT, 
and on identifying markers for treatment 
adaptation. To fully embrace the clinical 
potential of RT for the patient population as a 
whole – and individual patients in particular – 
we need to (i) determine the optimal total 
dose to control an individual patient’s tumors, 
(ii) identify optimal dose fractionation, (iii) 
explore the synergy of radiation with the 
patient’s immune system as well as with (iv) 
surgery, biological agents or 
chemotherapeutics. To prospectively 
determine individual treatment protocols, we 
must be positioned to reliably predict patient-
specific treatment responses.  
Advances in Science and Technology to Meet 
Challenges 
Quantitative approaches have shown great 
promise in retrospective analyses of radiation 
outcomes [74], correlation of pre-treatment 
tumor growth dynamics with radiation 
sensitivity [75], and optimization of dose 
fractionation in pre-clinical models [76]. To 
fully harness the potential benefits of 
integrated mathematical oncology, a close 
dialog between both mathematical and 
radiation oncology needs to be fostered [72]. 
With few high-resolution measurements on 
the cellular and sub-cellular level, hope lies in 
the anticipated collection of longitudinal data 
to inform differential equation and equation 
models to help simulate tumor growth and RT 
response dynamics.  
In a preclinical model of glioblastoma an 
integrated, iterative approach of experimental 
data informing a mathematical model, the 
model predicting optimal radiation schedules, 
and subsequent experimental validation 
yielded novel radiation fractionation protocols 
that significantly improve survival in mice 
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[76]. Due to the nature of the differential 
equation model, glioma stem cell division 
mechanisms were identified as contributing to 
improved survival, which will warrant further 
evaluation.  Challenges for translating 
preclinical models into the clinic include the 
scalability from a total of 10 Gy radiation dose 
in one week for a mouse to the patient who 
receives routinely 50-60 Gy over many weeks, 
as well as the logistics of scheduling irregular 
hyperfractionated protocols vis-à-vis the 
increasing trend for stereotactic radiation.  
Deriving an optimal total dose for individual 
patients was recently achieved by combining 
a molecular index of radiosensitivity (RSI), 
derived from gene expression analysis from 
pre-treatment biopsy tissue, with a 
mathematical model to derive a genomically 
adjusted radiation dose (GARD) [77]. To 
personalize dose fractionation, mathematical 
modeling of pre-treatment tumor growth 
between the diagnostic scan and radiation CT 
simulation has identified a proliferation 
saturation index (PSI, Figure 1) [78,79]. Based 
on PSI, patients can be non-randomly 
stratified into standard daily fractionation, 
hypofractionation, or twice-daily 
hyperfractionation protocols to achieve 
optimal tumor volume reduction. The 
estimation of GARD and PSI from, 
respectively, one or two patient-specific data 
points neglects the opportunity for multiple 
mathematical models to comparably simulate 
the data but potentially predict different dose 
and dose fractionations. Prospective clinical 
trials are necessary to fully evaluate the 
predictive power of mathematical model 
biomarkers. 
 
Figure 1. Pre-treatment tumor growth dynamics 
can be derived from volume measurements at 
diagnosis and treatment planning and used to 
calculate patient-specific PSI to predict RT 
responses. 
 
The timeliest and arguably most challenging 
research question for radiation oncology is 
the optimal dose and dose fractionation to 
induce robust antitumor immunity, and how 
to optimally sequence immunotherapeutics to 
harness RT-induced immune responses. Few 
radiation protocols have been evaluated 
specifically for immune activation, and even 
fewer protocols have been studied with 
limited immunotherapy agents in vivo.  
Evaluating all possible treatment 
combinations at different timing and at 
different radiation and immunotherapy doses 
is experimentally and clinically impossible. 
Mathematical modeling of tumor-immune 
interactions trained to simulate available 
experimental and clinical studies and 
validated on independent data sets may 
provide a powerful tool for in silico trials of 
untested treatment combinations [80]. 
Numerical simulations, optimization theory, 
and high throughput machine learning 
approaches are poised to help identify 
promising synergistic protocols to maximize 
RT-induced antitumor immunity for local and 
systemic tumor control. Model-predicted 
therapies would still need to be prospectively 
validated and, even if unsuccessful, the newly 
derived data will help to iteratively improve 
the model to inform the next generation of 
clinical trials.  
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Concluding Remarks 
RT is part of the therapy of more than half of 
all cancer patients, yet little research is 
directed to personalize radiation in the 
precision medicine era. Improving radiation 
treatment outcomes by a small margin will 
help more patients than the small target 
groups for novel clinical agents. We foresee a 
strong opportunity to integrate mathematical 
modeling with radiobiology and radiation 
oncology to address the immediate challenges 
for personalized RT. With a long history of 
successful physical models in radiation 
oncology, integration of mathematical 
modeling may be straight forward with a 
potentially large payoff.  
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Status 
Despite major advances in cancer therapies, 
most metastatic cancers remain fatal because 
tumor cells have a remarkable capacity to 
evolve drug resistance, both through genetic 
and non-genetic mechanisms. A common 
maxim in cancer treatment is to “hit hard and 
fast” through dose-dense strategies that 
administer the highest possible drug dose in 
the shortest possible time period. The 
maximum tolerated dose (MTD) principle has 
been the standard-of-care for cancer 
treatment for several decades. In fact all 
cancer drugs must go through a Phase I trial in 
which the MTD is established. The MTD 
strategy, however, only rarely cures patients 
with common disseminated cancers. An 
evolutionary flaw in this MTD strategy is the 
assumption that resistant populations are not 
present prior to therapy. It is now clear that 
resistant cancer cells are almost invariably 
present in the diverse cancer cell populations 
prior to treatment. This accounts for the 
consistent failure of MTD treatments to cure 
metastatic cancers but the consequences are 
actually worse. MTD therapy, is designed to 
kill as many cancer cells as possible, although 
intuitively appealing, actually accelerates the 
emergence of resistant populations due to a 
well-recognized Darwinian phenomenon 
termed “competitive release.” As illustrated in 
Figure 1, when high doses of drug are applied 
continuously, competitive release allows rapid 
emergence of resistant populations because 
of the combination of intense selection 
pressure and elimination of all potential 
“sensitive” competitors. An alternative 
evolution-based strategy delivers the 
minimum effective dose (MED) that 
deliberately maintains a persistent drug-
sensitive population. Treatment is then 
discontinued. Although the cancer population 
regrows, there is no selection for resistance so 
that it remains equally sensitive (Figure 1). 
Through repeated treatment cycles, the 
tumor remains under control for extended 
periods of time. In mathematical models and 
early clinical trials, we have found the length 
of each cycle is highly patient-specific and can 
range from 4 months to 1.5 years, but very 
much depends on the specific cancer under 
consideration. 
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We have termed this approach “adaptive 
therapy” and the eventual goal is to 
continuously adjust drugs, doses, and 
treatment schedules to prolong tumor control 
[81,82].  
 Furthermore, adaptive therapy is only 
one example of a larger class of evolutionary-
enlightened therapeutic approaches. 
Critically, as complex systems that span 
multiple spatial and temporal scales, these 
therapeutic perturbations of cancers often 
elicit non-linear dynamics so that outcomes 
can be predicted only using rigorously-
defined, biologically-parameterized, and 
clinically-driven mathematical models.  The 
Mathematical Oncology field must develop 
models that predict treatment responses in 
specific patients to enable the next generation 
of precision cancer medicine [83].  
 
Current and Future Challenges 
Optimal treatment strategies, based on 
observed molecular targets, have been a 
focus of “precision oncology” for some time. 
However, this approach has ignored a key 
piece of clinical reality – tumours are 
heterogeneous and evolve under the 
selection pressure of treatment. Therefore, 
even highly targeted and initially successful 
treatments almost inevitably fail as the cancer 
cells evolve adaptive strategies.  A number of 
mathematical techniques have been 
developed to model treatment outcomes. 
Evolutionary game theoretic approaches focus 
on the interactions between distinct 
subpopulations under different selection 
pressures in a frequency dependent manner 
[83,86-88]. Ordinary Differential Equation 
models can capture population dynamics but 
often at the cost of over simplifying the 
interactions. More complex approaches, that 
explicitly include space [84,85] or bridge 
multiple scales, have also been developed. 
However, a significant challenge with all of 
these approaches is how to calibrate them for 
a specific patient since some of the 
parameters are abstract e.g. fitness benefit or 
cost.  Further, even for minimal models some 
parameters may be impossible to measure in 
a patient.  
Assuming a model can be calibrated 
to a given patient, there is still a great deal of 
uncertainty regarding a specific fit since the 
model is gross simplification of reality. One 
approach to tackle this uncertainty is to 
develop multiple distinct models of the same 
tumour and generate an ensemble or 
consensus treatment plan, similar to 
hurricane prediction. Another is to 
deliberately consider all possible model 
parameter fits for a given patient as a cohort 
of patients that closely mimic the dynamics of 
the real patient. The successful in silico 
treatment strategies for the cohort then 
predict optimal therapy in the real patient. 
This “Phase i trial” approach [89] allows us to 
both run an exhaustive array of all possible 
treatment options on the cohort but also 
allows for the cohort to be further refined as 
additional response data is obtained 
throughout the course of treatment. Phase i 
trials can also serve to bridge the divide 
between homogenous preclinical models and 
heterogeneous clinical reality as well as 
allowing for optimal strategies to be 
developed and tested before a drug ever 
reaches a patient. 
This temporally changing treatment 
paradigm is a fundamental departure from 
the traditional fixed, one-size-fits-all strategy, 
and needs to be driven by a constant dialogue 
between model prediction and patient 
response. However, measuring and quantify 
patient tumour burden as well as 
intratumoural evolution during therapy using 
clinically-available patient data remains a 
major challenge.   
Figure 1.  Conventional high dose therapy (top) maximally selects for 
resistant phenotypes (pink). Adaptive therapy (bottom) maintains a 
small population of cells that are sensitive to treatment. While the 
resistant cells survive, the cost of resistance renders them less fit in 
the absence of therapy. Thus, sensitive cells return when therapy is 
removed, suppressing growth of the resistant population. 
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Advances in Mathematics, Technology, or 
Data to Meet Challenges 
There is a problem with big data in cancer.  Its 
spatial scale is entirely molecular, it averages 
the properties of a large and heterogeneous 
population of cancer cells, and it is both an 
invasive and destructive procedure such that 
it is often only obtained at a single time point. 
While genome scale data can direct the choice 
of specific cancer drugs and potentially 
classify patients into different categories, it is 
mostly utilized in a correlative manner. If we 
hope to build mechanistic predictive 
mathematical models, most of “big data” in 
cancer is the wrong data. It is not longitudinal, 
not spatial, only from one scale, averaged and 
homogeneous, not correlated or co-
registered, and not analyzed within an 
appropriate micro-environmental context. 
There is an urgent need to gather the right 
data that will allow us to better define the 
cancer system and connect the scales of 
cancer, bridging genotype to phenotype, cell 
to tissue,  organ to organism and individual to 
population. Because of the complex and 
dynamic nature of cancer it will not be 
sufficient to simply interpolate between data 
over these diverse spatial and temporal 
scales, rather we need to functionally 
integrate them through mathematical and 
computational models.  
For a cancer patient, the reality of 
monitoring disease burden over time with 
sufficient frequency and resolution is 
currently infeasible. New technologies need 
to be developed that can readily monitor 
tumor burden in non-invasive and cost-
effective ways that will directly facilitate the 
model prediction - treatment response loop 
of evolutionary therapy.  The right data will 
depend on the potential treatments available, 
the specific cancer under consideration, and 
the constrained reality of clinical practice. 
Serum markers are currently our best 
candidates. However, not all cancers have a 
good surrogate for burden (e.g. Prostate 
Specific Antigen). Circulating DNA and 
circulating tumor cells are emerging areas of 
intense investigation and hold significant 
promise but these markers focus on 
molecular scale changes. 
Thus, an additional challenge is linking 
mechanistic mathematical models to the 
genomic as well as the phenotypic scale. 
However, connecting the wealth of 
quantitative genomic information from a 
patient with functional cellular phenotypes 
remains an open question.  Some progress is 
being made using machine learning 
approaches and mathematical models are 
emerging of cancer evolution at the genomic 
scale [90]. 
Concluding Remarks 
There are currently 52 drugs approved for 
treatment of metastatic prostate cancer. Yet, 
every man who develops metastatic prostate 
cancer this year will not survive his disease. 
Throughout the past century, cancer therapy 
has focused entirely on the continuous 
development of new and more effective 
drugs. However, this enormous investment in 
time and resources has yet to significantly 
reduce the mortality rate of most common, 
adult metastatic cancers. Clearly, the drive to 
develop new and more effective cancer 
treatments is necessary. However, it is 
possible that the major impediment to 
improved outcomes in many cancers is not 
the absence of effective drugs but the 
absence of effective strategies. Thus, we view 
a key role for Mathematical Oncology is the 
development of patient calibrated 
mathematical models that integrate 
evolutionary first principles into cancer 
therapies to improve outcomes. 
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Status  
Somatic evolution is now recognized as a 
central force in the initiation, progression, 
treatment, and management of cancer. This 
has opened a new front in the proverbial war 
on cancer: focusing on the ecology and 
evolutionary biology of cancer. On this new 
front, we are starting to deploy new kinds of 
mathematical machinery: fitness landscapes 
and evolutionary games. 
A fitness landscape is a mathematical 
space where each point is a possible genotype 
or phenotype; two points are adjacent if they 
differ in a mutation or epimutation at a single 
locus; and each point has an associated fitness 
value. We often visualise evolutionary 
dynamics as ‘climbing up the hill’ of fitness 
values -- although in high dimensional spaces 
it might be better to replace the mountain 
metaphor by a maze metaphor [91].  
A central feature of fitness landscapes 
is the amount and kind of interactions 
between loci – such interaction is called 
epistasis. Synthetic lethality is a particularly 
important kind of epistasis for cancer cells.  If 
there are mutations at two loci which each 
change the fitness in one direction when they 
occur on their own, but in the opposite 
direction when they both occur together -- 
either bad + bad = good, or good + good = bad 
-- then the landscape is said to have reciprocal 
sign epistasis. It has been shown that any 
fitness landscape with more than one local 
peak must have reciprocal sign epistasis. 
Fitness landscapes conceptualize 
fitness as a single scalar value – a number. But 
a scalar can only express cell-autonomous 
effects, where fitness is inherent to the 
properties of a single cell. But cancer displays 
important non-cell-autonomous effects that 
allow fitness to depend on a cell's micro-
environmental context, including frequency of 
other cell types [92,93]. To accommodate this, 
evolutionary game theory (EGT) views these 
cell types as strategies, and models fitness as 
a function, which depends on the abundance 
of strategies in the population. On the 
surface, the games perspective is more 
expressive, since scalars can be represented 
as constant functions.  
But as always we pay for greater 
expressiveness by a loss of analysis 
techniques. For example, when dealing with 
fitness landscapes, we can often consider the 
strong-selection weak-mutation limit, which 
allows us to replace a population by a single 
point in the landscape. In the case of 
evolutionary games, such an approximation is 
unreasonable since it would eliminate the 
very ecological interactions that EGT aims to 
study. This means that the strategy space that 
can be analysed in an evolutionary game is 
usually much smaller than the 
genotype/phenotype space considered in a 
fitness landscape. Typical EGT studies 
consider just a handful of strategies (most 
often just two [92,94,95]), while fitness 
landscapes start at dozens of genotypes and 
go up to tens of thousands (or even hyper-
astronomical numbers of genotypes in 
theoretical work [91]). However, there is 
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ongoing work on adaptive landscapes that 
aims to combine the strengths of fitness 
landscapes and game theory. 
Game theory models have so far had 
more direct impact in oncology than fitness 
landscape models. The standard approach has 
been to develop a game theory model from 
the bottom up, starting from a reasonable 
reductive grounding and adding micro-
dynamic details. This is in keeping with the 
reductionist tactics used on the old cell and 
molecular biology front. For example, Basanta 
et al. [94] studied motility in cancer by 
defining two intuitive strategies: Go vs Grow. 
The first model included no spatial aspects; 
later work built on this by adding minimal 
spatial effects and considering the 
heterogeneity of spatial structure in a tumour 
[95]. This progression to more complicated 
and detailed models is a common pattern 
among EGT models in oncology. The other 
common aspect is that the games rely on 
biological or clinical intuition; the exact game 
parameters are seldom measured. This EGT 
perspective has helped oncologists to express 
a number of interesting theoretical 
consequences of non-cell autonomous 
processes, but has only recently started to be 
translated into direct experimental work. 
 
Current and Future Challenges  
Compared to EGT, fitness landscapes have not 
been as extensively used beyond mental 
models in oncology. But they have been 
central to work in understanding evolution of 
E. coli and yeast. The most notable example 
might be Lenski’s long-term evolution 
experiment with E. coli that has been 
propagating 12 initially identical populations 
for over 70,000 generations since 24 February 
1988. Another example is the study of the 
evolution of drug resistance in microbes [96], 
which has direct parallels to evolution of 
resistance in cancer.  
The key difficulty in developing fitness 
landscape models for oncology is that cancer 
cells are more complex, and oncological 
experimental systems are less well-controlled, 
than their microbial counterparts. In 
particular, micro-dynamical foundations of 
somatic evolution, reprogramming of human 
cells, and in vitro mutation operators are less 
well understood. The tactic from the old front 
of the molecular and cell biology of cancer 
would be to study and classify these micro-
dynamics in more and more detail. On the 
new front of somatic evolution we have a 
more promising tactic – abstraction. 
For a computer scientist, abstraction 
is a way to hide the complexity of a computer 
system. It is a way to make programs that can 
be used and re-used without having to re-
write all the code for each new computer. In 
this sense an algorithm is an abstraction of 
the actual sequence of bit flips that carry out 
the physical process that is computation. To 
turn it around: the physical process carried 
out by your computer is then an 
implementation of some abstract algorithm. 
Abstraction and implementation are in some 
sense dual to each other. 
Using this kind of abstraction, the 
tools of theoretical computer science can be 
introduced into oncology to reason rigorously 
about our models without knowing all the 
details of the implementation. For example, 
using computational complexity Kaznatcheev 
[91] conclude that there are ‘hard’ fitness 
landscapes where no evolutionary dynamic 
can find local fitness optima in polynomial 
time. This is an abstraction over the micro-
dynamical basis of evolution. If such fitness 
landscapes occur in tumours, then -- no 
matter how complicated the (re)programming 
of the cell or how strange and biased the 
mutation operator -- the cancer cells will not 
reach a local fitness peak and thus will always 
provide a moving target for therapy. It 
becomes an empirical problem to find out if 
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such landscapes occur in cancer. And it 
becomes a theoretical problem to discover 
other abstract properties of fitness landscapes 
that are robust under any implementation of 
the evolutionary micro-dynamic. 
Abstract objects or processes are 
multiply-realizable by a number of concrete 
objects or processes. The concrete objects 
might differ from each other in various ways, 
but if the implementations are ‘correct’ then 
the ways in which they differ are irrelevant to 
the abstraction. The abstraction is less 
detailed than the implementation, but 
captures essential features precisely.  
It might seem like connecting more 
closely to experiment must always make a 
model less abstract. But this is not always the 
case: the act of measurement itself can be a 
way to abstract. This is achieved with 
phenomenological or effective (instead of 
reductive) theories, and is easiest to illustrate 
in a game theory model. For example, 
Kaznatcheev et al. [93] developed a game 
assay based on the frequency and growth rate 
of types (as opposed to the more standard 
view of fitness of tokens or specific 
individuals). The focus on abstract types lets 
us absorb all the details of spatial structure, 
interaction length-scales, reproductive 
strategies, etc. into the measurement of the 
type fitness [93,97]. It is nature that figures 
out the particular computation that 
transforms token fitness into type fitness (see 
figure 1 for 3 examples) and we do not need 
to know it once we are working at the level of 
the abstract effective game: the abstract 
measurement is enough to derive the 
predictions of the model. A downside, of 
course, is that we cannot actually describe the 
specific way token fitness is translated into 
type fitness in our system. But future work 
can push the abstraction down, so that more 
details of the implementation – such as the 
effects of spatial structure – can be extracted 
[97]. This approach has already led to both 
new theoretical frameworks and new 
experimental techniques for analysing 
evolutionary games in microscopic cancer 
systems [93,97], but more focus on effective 
theories is needed – especially for fitness 
landscapes. 
 
 
Advances in Mathematics, Technology, or 
Data to Meet Challenges 
Although games can be viewed as a 
generalization of fitness landscapes, the game 
assay can only be used for a small strategy 
space. The size of a fitness landscape, 
however, is exponential in the number of loci, 
so it quickly becomes impossible to explicitly 
measure and record the fitness of every single 
possible genotype (or strategy). This barrier 
cannot be overcome by better technology or 
experiments. Instead, we need to focus on 
fitness landscape models with compact 
representations that are learnable from a 
polynomial number of samples. These 
compact representations are akin to rules for 
genotype-phenotype maps (where the 
relevant phenotype is fitness): they specify a 
rule for computing the fitness value from the 
genotype (or at least the relative order of 
fitness), instead of explicitly storing a fitness 
value for each genotype. 
To find compact representations it is 
tempting to turn to existing representations 
like oncogenetic trees or cancer progression 
Figure 1.  The same effective game [97] implemented 
by three different population structures and reductive 
games; from left to right: inviscid population, random 3-
regular graph, experimental in vitro non-small-cell lung 
cancer [93]. 
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models (CBN & CARPI, in particular), but these 
models cannot express the reciprocal sign 
epistasis that makes for interesting fitness 
landscapes [98]. Instead, we need models that 
can represent gene-interaction networks with 
low-order epistasis (a classic example would 
be spin glasses) [91,99]. These gene-
interaction networks can express reciprocal 
sign epistasis. Most importantly, such 
networks can be inferred from polynomially-
sized local fitness landscapes: from fitness 
values just a couple of mutations away from a 
wildtype, instead of measuring every possible 
combination of mutations. Such local 
landscapes have been measured in yeast 
[100], similar measurement techniques need 
to be developed for cancer systems. 
 
Concluding Remarks 
On this new front in the war on cancer that 
was opened by somatic evolution, we not only 
need new mathematical machinery, like 
fitness landscapes and evolutionary games, 
but also new tactics, like abstraction. To 
handle complex systems like cancer where we 
do not know the detailed evolutionary micro-
dynamics we need abstract models that 
extend the tools and techniques developed in 
microbiology and ecology to handle multiple-
realizability. The lesson from computer 
science is that rigorous abstraction provides 
great theoretical power.  And experimentally, 
we need to recognize that abstract is not the 
opposite of empirical.  Abstract models can 
serve as phenomenological (or ‘effective’) 
theories that use carefully defined 
measurements to account for multiple-
realizability from unknown micro-dynamic 
details. Developing this approach will allow us 
to better use the mathematical machinery of 
fitness landscapes and evolutionary games for 
understanding and treating cancer. 
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Status 
Predicting, detecting, and preventing 
drug resistance is an enduring challenge in 
clinical oncology. The initial development of 
targeted therapies provided hope that 
targeting the unique molecular drivers of a 
tumour would allow for more precise 
treatment with fewer clinical side effects. 
However, in many cases, after a transient 
killing of tumour cells, drug resistance leads to 
therapeutic failure. Indeed, cancer is an 
intrinsically evolutionary process in which cell 
populations comprising the tumour adapt and 
evolve in response to the selective pressures 
placed upon them, particularly anti-cancer 
therapies [101]. Cancer treatment is subject 
to the same dilemma of drug resistance that 
has complicated the treatment of infections 
with antibiotics [102]. In both cancer and 
infectious diseases, drugs apply a selective 
pressure that yields higher frequencies of 
phenotypes better-suited to survive in their 
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environment. Even the most advanced 
therapies are ultimately at the mercy of the 
Darwinian principles of evolution. 
When it comes to discerning the 
separated time scales of this evolution of drug 
resistance, we have found a singularly focused 
strategy to be insufficient. As we strive for our 
work to tangibly affect clinical care, the fields 
of population genetics, evolutionary and 
adaptive dynamics, and statistical physics may 
offer models and tools that provide an 
improved understanding of the temporal 
dynamics of resistance evolution and the 
necessary timescales of potential 
interventions (Figure 1). Two specific 
examples from the emerging field of 
evolutionary therapy have demonstrated how 
the marriage of disparate theoretical and 
experimental tools have brought us closer 
toward the goal of evolutionarily informed 
therapy. 
 
 
One body of work utilizes 
evolutionary game theory (EGT) to deliver 
insights into the qualitative relationships 
between the “players” in the tumour micro-
environment. Another complimentary 
strategy models cancer evolutionary dynamics 
on fitness landscapes and is more amenable 
to genomic sequencing data and addressing 
tumour heterogeneity. 
While we only discuss two models 
here with several unanswered questions 
standing in the way of their full potential, we 
believe they represent research strategies 
that are ripe for the interdisciplinary scientific 
groups and institutes of today and beyond. 
 
Current and Future Challenges 
Evolutionary game dynamics have 
been found to describe diverse phenomena in 
cancer ranging from IGF-II production in 
pancreatic tumours to tumour-stroma 
interactions in prostate cancer [103, 104]. 
While these models may yield insights into 
the qualitative relationships between the 
players in the tumour micro-environment, it is 
unclear if the evolutionary game modelled in 
different cancers is applicable to other 
cancers, or even every patient with a given 
cancer. Furthermore, the payoff matrix used 
to describe the games played in most models 
of evolutionary games is not empirically 
derived, but rather inferred from clinical 
intuition. It seems that a means of measuring 
these micro-dynamic interactions among 
tumour cells in any given tumour is necessary.  
An additional drawback of the EGT 
formalism is the difficulty in using it to 
characterize the vast heterogeneity and 
mutational activity that are critical 
components of the evolution of drug 
resistance. Current biological methodologies 
may only allow for the study of interactions 
between a few cell types. Studying fitness 
landscapes may address this issue of 
accounting for tumour heterogeneity. Fitness 
landscapes are a genotype-phenotype map, in 
which each allele is assigned a corresponding 
fitness and set of neighbouring alleles. 
Suggested first by Sewall Wright, in the 
canonical model of fitness landscapes, each 
allele can be represented as a string of ones 
and zeros corresponding to mutated and wild-
type alleles, respectively. The entire landscape 
can be represented as a network of these bit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Correspondence of research strategies to the process of 
tumour evolution: Tumour heterogeneity is driven by clonal populations 
traversing evolutionary trajectories, the interactions between them, and 
the diversification that results. The milieu of molecular mechanisms that 
can be observed at the time of biopsy potentially confers finite drug 
sensitivity phenotypes. 
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strings with a hypercubic topology. Each node 
has its own fitness, and evolution proceeds as 
a biased random walk through the winding 
maze of genotype space, as it tends toward 
the most fit genotypes available to it [105].  
Any environmental condition (i.e. 
cancer therapies) can apply a selective 
pressure to a population (i.e. a tumour) that 
specifies a corresponding fitness function over 
the domain of genotype space (Figure 2D,E). 
For fitness landscapes to be clinically useful 
there are challenges to be overcome. These 
include, but are not limited to: measurement, 
definition, and inference of fitness landscapes 
in clinically-relevant contexts and 
determination of appropriate time-scales of 
possible interventions. 
 
Advances in Mathematics, Technology, or 
Data to Meet Challenges 
We have recently suggested one 
method to experimentally parametrize EGT 
matrices: the evolutionary game assay. We 
observed in our cultures of alectinib resistant 
and sensitive lung cancer cells a linear 
frequency dependence of resistant cell 
growth rate on the proportion of sensitive 
cells, allowing us to represent the interactions 
in the four conditions studied as a two-
strategy matrix game and infer the games 
played [93]. We showed that in our 
experimental system of drug resistant and 
sensitive cells, in the presence of alectinib and 
stromal cells, a qualitatively different game is 
being played (Figure 2A,B). Our evolutionary 
game assay is designed specifically to capture 
the “effective” game being played. Along with 
work aimed at characterizing how spatial 
information implies information about 
tumour-environment interactions, our assay 
to empirically measure games may be used to 
design clinical trials in any cancer type [106, 
107].  
To address our game theory assay’s 
inadequacy at accounting for tumour genetic 
heterogeneity, we turned to fitness 
landscapes. Our theoretical work has revealed 
an interesting feature of an evolving 
population subjected to sequential drugs: 
evolution through these sequential drug 
landscapes is irreversible. Given complete 
information of each fitness landscape, this 
feature allows for what we call “steering” 
using drug sequences, that is, using drugs to 
purposely push the cancer cell population to 
states of sensitivity from which resistance is 
less likely to be reached [96]. This steering of 
evolutionary dynamics reveals yet another 
strategy for evolutionary therapy. We propose 
that with the advent of computational 
methods to infer fitness landscapes on 
temporal and genomic scales, one could 
design patient-specific steering drug regimens 
to minimize drug resistance. We have 
performed further high throughput evolution 
experiments that suggest its feasibility [108].  
 
Addressing the previously described 
challenges of utilizing fitness landscapes to 
optimize treatment sequence regimens may 
require exploiting the close analogy between 
evolutionary fitness landscapes and energy 
landscapes in other contexts. Techniques 
from statistical physics that allow for the 
inference of properties of energy landscapes 
through experimental probes or protocols 
that vary the stochastic dynamics of these 
landscapes over time, can potentially be 
adapted to the evolutionary context.  
 
Concluding Remarks 
Our EGT assay and evolutionary steering 
method provide examples of how 
understanding the evolutionary dynamics of 
cancer through both theoretical and 
molecular biological tools can lead to more 
effective treatments for patients. In the 
future, this can lead to treatment sequence 
regimens optimized to steer a tumor away 
from resistance and treatments that alter the 
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tumor microenvironment to modulate the 
evolutionary game being ‘played’ and 
decrease the resulting proportion of resistant 
cells. As both frameworks highlighted here 
have their advantages and drawbacks, it is 
only by exploring them in concert and 
considering how they may complement each 
other that we can apply them most 
effectively. Fitness landscapes’ failure to 
address the tumour micro-environment, for 
instance, motivations exploration of EGT, 
which is well suited to examine such 
interactions. To look forward we must look 
backward, extending and  
 
blending these readily available tools. The 
application of these well-established theories, 
methodologies, and drugs, re-imagined and 
reconsidered in novel ways is a promising 
path forward to overcome therapeutic 
resistance in cancer. 
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